Biocom - Life Sciences Association of California
Close
Call
Profile
San Diego  |   Los Angeles  |   Washington, DC  |   Tokyo
cONTENT bLOCK
Left
Left
https://www.biocom.org/servlet/servlet.ImageServer?id=015F0000007NwSsIAK&oid=00DA0000000Kz7JMAS  

Why the Current CRO Model May Be Failing Developers, Investors and Pa

 
When:
Wednesday, June 14 2017 - Wednesday, June 14 2017
8:00 AM - 10:00 AM

Add to Calendar America/Los_Angeles Why the Current CRO Model May Be Failing Developers, Investors and Pa The first in a series of “Concept to Commercialization” presentations, this lecture will examine why the current CRO model may be failing developers, investors and patients.  Does a new model CRO need introduction to the industry?  Yes, according to pharmaceutical leader James Nolan, one that includes these four, key elements and available at the earliest stages of development:
 
BIOCOM - McGraw Boardroom Biocom false MM/DD/YYYY

Where:
BIOCOM - McGraw Boardroom
10996 Torreyana Road Suite 200
San Diego, California 92121
Registration Deadline:
Tuesday, June 13 2017
12:00 PM
Register


The first in a series of “Concept to Commercialization” presentations, this lecture will examine why the current CRO model may be failing developers, investors and patients.  Does a new model CRO need introduction to the industry?  Yes, according to pharmaceutical leader James Nolan, one that includes these four, key elements and available at the earliest stages of development:
 
  • A reimbursement strategy
  • Regulatory experts
  • Pre-IND evaluation capabilities
  • Patient access experts.
 
These added capabilities will allow CROs to separate themselves in a highly competitive industry. Mr. Nolan will also detail key issues complicating the concept to commercialization path for drug developers.

Speaker: 
James Nolan, CEO, InClinica
 

Sponsored By: